Shingrix vaccine linked to lower dementia risk
Analysis based on 14 articles · First reported Aug 25, 2026 · Last updated Aug 28, 2026
The study could boost demand for Shingrix, potentially increasing sales for GSK plc and reinforcing its market position in the shingles vaccine market. It may also spur further research into vaccine neuroprotective benefits, influencing pharmaceutical investment and public health recommendations.
A large observational study published in Annals of Internal Medicine found that older adults who received the Shingrix shingles vaccine after entering a skilled nursing facility had a 24% lower risk of being diagnosed with dementia over four years compared to unvaccinated peers. The study analyzed United States — Medicare data and electronic health records from 509,926 adults aged 66 and older admitted to more than 5,500 U.S. skilled nursing facilities between 2017 and 2022. Only 8,843 participants received at least one dose of Shingrix. Dementia developed in 18.8% of vaccinated participants versus 24.6% of unvaccinated, suggesting about one in 17 dementia cases could potentially be prevented. The study, led by Kaley Hayes of Brown University, used target trial emulation to strengthen causal inference but cannot prove causation. Vaccinated individuals were slightly younger and healthier, and the authors adjusted for these factors. The findings align with earlier studies on older shingles vaccines. The study was funded by GSK plc, the manufacturer of Shingrix, which had no control over the research. Further clinical trials are needed to confirm the link.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard